Oxurion Receives Transparency Notifications from Negma Group

Leuven, BELGIUM, Boston, MA, US – February 24, 2022 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on February 21, 2023 from Negma Group Ltd. indicating that as of February 16, 2023, it held no shares of the then outstanding 564,210,937 shares, and therefore crossed below the threshold (3%) by virtue of disposal of voting securities. See Annex 1

Oxurion received a transparency notification on February 21, 2023 from Negma Group Ltd. indicating that as of February 15, 2023, it held 35,314,661 shares of the then outstanding 564,210,937 shares, and therefore crossed above the threshold (5%) by virtue of acquisition of voting securities. See Annex 2

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements


Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV	<u>US</u>
Tom Graney	Conway Communications
Chief Executive Officer	Mary T. Conway
Tel: +32 16 75 13 10	mtconway@conwaycommsir.com
" tom.graney@oxurion.com	
	ICR Westwicke
Michael Dillen	Christopher Brinzey
Chief Business Officer	Tel: +1 617 835 9304
Tel: +32 16 75 13 10	Chris.Brinzey@westwicke.com
michael.dillen@oxurion.com	

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1



9) Denominator

564,210,937 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of vot	ing rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Elaf Gassam	0	0		0.00%	
Negma Group Investment Ltd.	0	0		0.00%	
Negma Group Ltd.	35,314,661	0		0.00%	
Subtotal	35,314,661				




- +

B) Equivalent financial instruments	After the transaction						
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement	
							+
TOTAL							
The totals will be updated once you have clicked on <calculate></calculate>							

TOTAL (A & B)	TOTAL (A & B)		
	CALCULATE	0	0.00%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable



12) In case of proxy voting for only one GM

Holder	will cease to hold / will hold again	0	voting rights as of	(DD/MM/YYYY)
13) Additional information				

Done at	Dubai, United Arab Emirates			
On	21/02/2021	(DD/MM/YYYY)		
Name & capacity	Elaf Gassam, Director		Signature	EP

ANNEX 2

FSMA FINANCIAL SER MARKETS AUT			Transparency notification Form TR-1 BE PART I	
1) Status of the notification				
Fina	al			
2) Issuer				
	URION 11-620-924			
3) Reason for the notification				
Acq	uisition or disposal of voting securitie	es or voting righ	its	+
4) Notification by				
A pa	arent undertaking or a controlling pers	son		+
5) Persons subject to the notific	ation requirement			
	Name		Address (for legal entities)	_
Elaf	Gassam			-
	egma Group Investment Ltd.		Unit 1 Level 28, ICD Brookfield Place, DIFC, Dubai (United Arab Emirates) Craigmuir chambers, Road Town, Tortola, VG 1110 (British Virgin	-
Ne	egma Group Ltd.		Islands)	+
 Persons that dispose of votin 	i <u>g rights</u> (only to be filled in if an	t. 7 of the Lav	v applies)	
	Name		Address (for legal entities)	
				+
Ple: per	ase continue entering the informati sons referred to in Sections 5 and (ion in <i>part II</i> c 6	oncerning the Part II	
7) Date on which the threshold i	is crossed			
		15/02/2023	(DD/MM/YYYY)	
B) Threshold that is crossed (in	%)			
		5		
🗊 If th	he holding has fallen below the low	est threshold,	you have the option of not entering any numbers in Section 10	
I				

9) Denominator



10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of vot	# of voting rights		ing rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Elaf Gassam	0	0		0.00%	
Negma Group Investment Ltd.	0	0		0.00%	
Negma Group Ltd.	0	35,314,661		6.26%	
Subtotal		35,314,661		6.26%	

-
-
-
+

	TOTAL	35,314,661	0	6.26%	0.00%	
Û	Start with "groups" of holders. Add subtotals with 2 , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity.					

The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction						
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement	
							+
TOTAL			0	0.00%			
The totals will be updated once you have clicked on <calculate></calculate>							
	TOTAL (A & B)			# of voting rights	% of voting rights		

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable



CALCULATE 35,314,661

5-

Sign

6.26%

12) In case of proxy voting for only one GM

Name & capacity Elaf Gassam, Director

Holder	will cease to hold / will hold again	0	voting rights as of	(22/10/17/17/	
--------	---	---	---------------------	---------------	--

13) Additional information

Done at	Dubai, United Arab Emirates		
On	21/02/2023	(DD/MM/YYYY)	